The role of FDG PET/CT or PET/MRI in assessing response to neoadjuvant therapy for patients with borderline or resectable pancreatic cancer: a systematic literature review.
The aim of the present systematic review is to examine the role of fluorodeoxyglucose (FDG) positron emission tomography (PET) associated with computed tomography (CT) or magnetic resonance imaging (MRI) in assessing response to preoperative chemotherapy or chemoradiotherapy (CRT) for patients with borderline and resectable pancreatic ductal adenocarcinoma (PDAC). Three researchers ran a database query in PubMed, Web of Science and EMBASE. The total number of patients considered was 488. The most often used parameters of response to therapy were the reductions in the maximum standardized uptake value (SUVmax) or the peak standardized uptake lean mass (SULpeak). Patients whose SUVs were higher at the baseline (before CRT) were associated with a better response to therapy and a better overall survival. SUVs remaining high after neoadjuvant therapy correlated with a poor prognosis. Available data indicate that FDG PET/CT or PET/MRI can be useful for predicting and assessing response to CRT in patients with resectable or borderline PDAC.
['Evangelista|Laura|L|http://orcid.org/0000-0002-5955-9488', 'Zucchetta|Pietro|P|', 'Moletta|Lucia|L|', 'Serafini|Simone|S|', 'Cassarino|Gianluca|G|', 'Pegoraro|Nicola|N|', 'Bergamo|Francesca|F|', 'Sperti|Cosimo|C|', 'Cecchin|Diego|D|']
D000328:Adult D019788:Fluorodeoxyglucose F18 D006801:Humans D008297:Male D008875:Middle Aged D020360:Neoadjuvant Therapy D010190:Pancreatic Neoplasms D000072078:Positron Emission Tomography Computed Tomography
FDG PET/CT PET/MRI Neoadjuvant therapy Pancreatic cancer